Organization
Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Attica, Greece
1 abstract
Abstract
Ocular adverse events in transplant ineligible patients with newly diagnosed multiple myeloma treated with belantamab mafodotin plus lenalidomide/dexamethasone from the phase 1/2 BelaRd study.Org: Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Attica, Greece, Health Data Specialists, Dublin, Ireland, Dublin, Ireland, Alexandra Hospital, Athens, Greece, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Attica, Greece, Health Data Specialists, Dublin, Ireland, Alexandra Hospital, Athens, Greece,